Adult Clinical Trials

Lymphomas - Non-Hodgkin's lymphoma and Hodgkin's disease

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Lymphoma Clinical Trials Office at 919.681.4769.

7 trials identified.

CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Julie Warzecho, RN
Phone: 919.681.4769
Reference Number: 00044123
View this trial at ClinicalTrials.gov

PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (CC-5013) PLUS R-CHOP CHEMOTHERAPY (R2-CHOP) VERSUS PLACEBO PLUS R-CHOP CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED ACTIVATED B-CELL TYPE DIFFUSE LARGE B-CELL LYMPHOMA
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: Hematology Malignancy Oncology Research Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00058584
View this trial at ClinicalTrials.gov

CALGB 51101: A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: LYMPHOMA CLINICAL TRIALS OFFICE
Phone: 919.681.4769
Reference Number: 00062558
View this trial at ClinicalTrials.gov

A Phase 1/2 Study Evaluating brentuximab vedotin in Combination With nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: Hematology Malignancy Oncology Research Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00064494
View this trial at ClinicalTrials.gov

A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: LYMPHOMA CLINICAL TRIALS OFFICE
Phone: 919.681.4769
Reference Number: 00066502
View this trial at ClinicalTrials.gov

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00073198
View this trial at ClinicalTrials.gov

PHASE 1 STUDY OF ACTR087, AUTOLOGOUS T LYMPHOCYTES EXPRESSING ANTIBODY COUPLED T-CELL RECEPTORS (CD16V-41BB-CD3), IN COMBINATION WITH RITUXIMAB, IN SUBJECTS WITH RELAPSED OR REFRACTORY CD20-POSITIVE B-CELL LYMPHOMA
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Anne Beaven
Contact: BMT CELLULAR THERAPIES Oncology Clinical Trials Office
Phone: 919.681.4769
Reference Number: 00073532
View this trial at ClinicalTrials.gov